Cannabis News Box

GW Pharmaceuticals turns over $108M in Q4 sales thanks to CBD-based medicine

GW Pharmaceuticals turns over $108M in Q4 sales thanks to CBD-based medicine

Bethan Rose Jenkins, Cannabis News Writer/Editorial

January 27, 2020

Following the EU approval of a cannabis-derived epilepsy treatment called Epidiolex, British drugs company GW Pharmaceuticals is experiencing a major surge in sales. Headquartered in London, GW Pharma recently revealed its latest sales figures to investors; $108 million during the last quarter of 20...

Annual J.P. Morgan Healthcare Conference